Ruben Mesa, MD
Enriched profilePresident & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Charles L. Spurr, MD Professor of Internal Medicine, Wake Forest University School of Medicine · Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Ruben Mesa is President & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Charles L. Spurr, MD Professor of Internal Medicine, Wake Forest University School of Medicine at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. OpenAlex indexes 1,282 publications with 45,977 citations (h-index 97); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Ruben Mesa, MD, is President & Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center. The public record shows 1,282 publications with 45,977 citations (h-index 97), centered on Hematology. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 20 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Hematology
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 52 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.uthscsa.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Sponsor: John Mascarenhas
- Calm for Cancer Patients Receiving Chemotherapy
Sponsor: The University of Texas Health Science Center at San Antonio
Industry payments
Updated 27 Aug 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202512 payments$27,136openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20254 payments
- Sumitomo Pharma America, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor39%Jakafi100%Part D<11 patientsInterferon alfa-2b18.8%Besremi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patients
University of Texas Hlth Science Center
FY2026$589,612R01CA262041
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Expert Validation of an Artificial Intelligence-Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer.
JCO oncology practice
Article2026 - Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.
Clinical and experimental allergy
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ruben-mesa-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ruben-mesa-md-0b94425
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
bloodcancerunited.org/person/ruben-mesa-md-facp
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗ - Other
empoweredpatientradio.com/breakthrough-treatment-for-myelofibrosis-changes-care-options-with-dr-ruben-mesa-atrium-health
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →empoweredpatientradio.com ↗ - Other
mpnresearchfoundation.org/news/qa-with-dr-ruben-mesa
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Mayo Clinic College of Medicine and Science
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atriumhealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wakehealth.edu ↗
- Board certified
Internal Medicine and Hematology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atriumhealth.org ↗
Editorial & leadership roles
journal and society appointments- President & Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center (also Atrium Health Levine Cancer)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atriumhealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wakehealth.edu ↗
- Editor-in-Chief
Current Hematology Malignancy Reports
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Awards & honors
honors on the public record- 2025 ASH Ernest Beutler Lecture and Prize (American Society of Hematology)
for contributions to myeloproliferative neoplasm research including development of the MPN-SAF/MSAF patient-reported outcome tools
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - 2024 Distinguished Alumnus
University of Illinois Urbana-Champaign College of Liberal Arts and Sciences
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aaci-cancer.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aaci-cancer.org ↗
Secondary affiliations
appointments beyond the home institution- Wake Forest University School of Medicine
Vice Dean for Cancer Programs; Charles L. Spurr, MD Professor of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wakehealth.edu ↗ - American Cancer Society
Board of Directors
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.org ↗
Media & interviews
press, podcasts and appearances- ASCO Post video (EHA 2021 Virtual Congress): myelofibrosis
transfusion independence, and momelotinib
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- OncLive On Air podcast with Aaron Gerds
MD, management strategies and emerging agents in myelofibrosis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic